Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry-Reference-Cited by-同舟云学术

Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry

Published:2022-11-04 Issue:12 Volume:12 Page:2797-2815
ISSN:2193-8210
Container-title:Dermatology and Therapy
language:en
Short-container-title:Dermatol Ther (Heidelb)

Author:

Lockshin Benjamin,Harrison Ryan W.,McLean Robert R.,Crabtree Margaux M.,Konicek Bruce W.,Zhu Baojin,Malatestinic William N.,Atiya Bilal,Murage Mwangi J.,Burge Russel T.

Funder

Eli Lilly and Company

Publisher

Springer Science and Business Media LLC

Subject

Dermatology

Link

https://link.springer.com/content/pdf/10.1007/s13555-022-00834-7.pdf

Reference41 articles.

1. Georgakopoulos JR, Phung M, Ighani A, Yeung J. Efficacy and safety of switching to ixekizumab in secukinumab nonresponders with plaque psoriasis: a multicenter retrospective study of interleukin 17A antagonist therapies. J Am Acad Dermatol. 2018;79(1):155–7. https://doi.org/10.1016/j.jaad.2018.01.003.

2. Ronholt K, Iversen L. Old and new biological therapies for psoriasis. Int J Mol Sci. 2017. https://doi.org/10.3390/ijms18112297.

3. Sawyer LM, Malottki K, Sabry-Grant C, et al. Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response. PLoS ONE. 2019;14(8): e0220868. https://doi.org/10.1371/journal.pone.0220868.

4. Honda H, Umezawa Y, Kikuchi S, et al. Switching of biologics in psoriasis: reasons and results. J Dermatol. 2017;44(9):1015–9. https://doi.org/10.1111/1346-8138.13860.

5. Loft N, Halling AS, Egeberg A, Skov L. Efficacy of a second interleukin 17 inhibitor in patients with psoriasis: a systematic review and meta-analysis. J Am Acad Dermatol. 2021;84(1):130–8. https://doi.org/10.1016/j.jaad.2020.07.085.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sequencing of Targeted Therapy in Psoriasis: Does it Matter?;American Journal of Clinical Dermatology;2024-07-13

2. Six-Month Real-World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry;Drugs - Real World Outcomes;2024-06-24

3. Relationship of Soluble Lectin‐Like Low‐Density Lipoprotein Receptor‐1 (sLOX‐1) With Inflammation and Coronary Plaque Progression in Psoriasis;Journal of the American Heart Association;2023-11-21

4. Real‐world drug survival of Brodalumab, in patients with psoriasis switched from Ixekizumab: Results of a single centre retrospective study (BroSwitch);JEADV Clinical Practice;2023-05-18